Home » Stocks » Principia Biopharma

Principia Biopharma Inc. (PRNB)

Sep 25, 2020 - PRNB was delisted after being acquired by SNY
Stock Price: $100.05 USD 0.00 (0.00%)
Updated Sep 28, 2020 4:00 PM EDT

Stock Price Chart

Key Info

Market Cap 3.32B
Revenue (ttm) 50.00M
Net Income (ttm) -68.91M
Shares Out 33.21M
EPS (ttm) -2.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Sep 28, 2020
Last Price $100.05
Previous Close $100.05
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 99.95 - 100.37
Day's Volume 0
52-Week Range 25.35 - 101.89

More Stats

Market Cap 3.32B
Enterprise Value 3.02B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 33.21M
Float 27.31M
EPS (basic) -2.47
EPS (diluted) -2.27
FCF / Share -2.87
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.58M
Short Ratio 0.50
Short % of Float 5.79%
Beta 0.86
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 66.45
PB Ratio 9.45
Revenue 50.00M
Operating Income -74.17M
Net Income -68.91M
Free Cash Flow -95.07M
Net Cash 302.40M
Net Cash / Share 9.11
Gross Margin 70.32%
Operating Margin -148.35%
Profit Margin -137.80%
FCF Margin -190.14%
ROA -16.03%
ROE -26.40%
ROIC -28.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 1
Overweight 0
Hold 5
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

(3.81% upside)
Current: $100.05
Target: 103.86
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-49.14%1217.65%--
Gross Profit35.1669.145.25-
Operating Income-58.7717.14-26.59-27.05
Net Income-53.794.92-28.70-30.64
Shares Outstanding25.787.620.570.51
Earnings Per Share-2.090.57-50.37-59.89
Operating Cash Flow-42.55-21.1726.85-24.84
Capital Expenditures-2.17-1.07-0.09-0.01
Free Cash Flow-44.72-22.2426.76-24.86
Cash & Equivalents31617741.155.97
Total Debt---14.45
Net Cash / Debt31617741.15-8.49
Book Value359170-143-117
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Principia Biopharma Inc.
Country United States
Employees 124
CEO Martin Babler

Stock Information

Ticker Symbol PRNB
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PRNB
IPO Date September 14, 2018


Principia Biopharma, a late-stage biopharmaceutical company, focuses on developing novel therapies for immune-mediated diseases. The company is developing rilzabrutinib, an inhibitor that is in Phase III clinical trials for the treatment of pemphigus, a chronic skin disease, as well as and pemphigus foliaceus; in a Phase 1/2 trial for the treatment of immune thrombocytopenia; and a Phase 2 trial for the treatment of IgG4-related disease. It is also developing PRN2246/SAR442168, an inhibitor, which is in Phase Ii clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; and PRN473, a drug candidate that is in Phase I clinical trial for the treatment of immune-medicated diseases. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California. As of September 25, 2020, Principia Biopharma Inc. operates as a subsidiary of Sanofi.